Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Portfolio Pulse from
Eli Lilly has launched new 7.5 mg and 10 mg Zepbound vials priced at $499 per month and reduced prices for 2.5 mg and 5 mg vials. These are available through the Zepbound Self Pay Journey Program, bypassing third-party supply chains.
February 25, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has introduced new Zepbound vial doses and reduced prices for existing ones, enhancing affordability for self-pay patients through the Zepbound Self Pay Journey Program.
The launch of new vial doses and price reductions for Zepbound is likely to positively impact Eli Lilly's stock in the short term. The initiative to offer these through a self-pay program could increase accessibility and sales, potentially boosting revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100